ESC 365 - Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition

ESC Premium Access

Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition

Session: PCSK9 inhibition - cholesterol reduction and beyond

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor J. Jukema (Leiden, NL)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

20 presentations

0 follower

3 more presentations in this session

A global view: the rationale for aggresive LDL lowering

Speaker: Professor S. Nissen (Cleveland, US)

Cholesterol metabolism and the role of PCSK9

Speaker: Professor S. Nicholls (Melbourne, AU)

Are there effects of PCSK9 inhibitors beyond cholesterol lowering?

Speaker: Professor B. Cariou (Nantes, FR)

Access the full session

PCSK9 inhibition - cholesterol reduction and beyond

Speakers: Professor J. Jukema, Professor S. Nissen, Professor S. Nicholls, Professor B. Cariou

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources